Decision Resources

Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

WIRB Copernicus Group

Report: cancer immunotherapy market to hit $9B globally by 2022

Wednesday, July 9, 2014 12:05 PM

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

More... »

CRF Health eCOA webinar series

Report: U.S. Alzheimer's imaging agent market will grow as reimbursement improves

Thursday, February 13, 2014 03:03 PM

The U.S. Alzheimer's imaging agent market will grow dramatically over the next 10 years, according to Decision Resources Group. Currently, Eli Lilly's Amyvid, launched in June 2013, is the only FDA-approved product available, but GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticalsare all poised to launch products in the U.S. in the next few years.

More... »

Decision Resources Group acquires Relay Technology Management

Wednesday, January 8, 2014 01:31 PM

Piramal Enterprises' information management subsidiary, Decision Resources Group, a research and advisory firm focusing on high-value healthcare insights and analytics, has acquired Relay Technology Management, a data analytics company focused on the life sciences industry.

More... »

Report: Pharma should factor medication adherence into drug development

Monday, December 2, 2013 10:34 AM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has a new strategic insights report that found in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process.

More... »

Report: use of biomarkers outside oncology trials increasing

Thursday, November 14, 2013 11:00 AM

Decision Resources, a research and advisory firm focusing on pharmaceutical and healthcare issues, found while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions and their use in clinical trials of drugs outside of oncology is building.

More... »

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Monday, October 28, 2013 02:22 PM

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

More... »

Report: Increase in Biopharma new product launches originating from in-licensing deals

Friday, October 18, 2013 01:51 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, reports that biopharma companies industry-wide are increasingly moving away from in-house research and toward acquisitive strategies to build their portfolios and grow sales. According to findings from the Strategic Insights report, the fraction of new product launches that originate from in-licensing has increased dramatically over the last decade. In 2012, 53% of new product launches were in-licensed during development, as compared to an average of 32% between 2003 and 2012.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs